Cardiovascular Systems Inc (NASDAQ:CSII) – Stock analysts at Leerink Swann decreased their Q3 2018 earnings per share (EPS) estimates for shares of Cardiovascular Systems in a note issued to investors on Wednesday. Leerink Swann analyst D. Antalffy now anticipates that the medical device company will post earnings per share of ($0.01) for the quarter, down from their prior estimate of $0.04. Leerink Swann has a “Outperform” rating and a $30.00 price objective on the stock. Leerink Swann also issued estimates for Cardiovascular Systems’ FY2018 earnings at ($0.08) EPS, Q2 2019 earnings at ($0.02) EPS, FY2019 earnings at $0.02 EPS, FY2020 earnings at $0.24 EPS and FY2022 earnings at $0.57 EPS.
Several other analysts also recently commented on CSII. Zacks Investment Research upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Friday. ValuEngine downgraded Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. BidaskClub downgraded Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Raymond James Financial restated a “hold” rating on shares of Cardiovascular Systems in a research note on Monday, December 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $36.00 target price (down from $37.00) on shares of Cardiovascular Systems in a research note on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $27.00.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative return on equity of 0.51% and a negative net margin of 1.62%. The firm had revenue of $52.63 million during the quarter, compared to the consensus estimate of $53.39 million. During the same period last year, the business posted $0.03 EPS. The business’s revenue was up 5.2% compared to the same quarter last year.
Several institutional investors and hedge funds have recently modified their holdings of CSII. BlueCrest Capital Management Ltd bought a new position in Cardiovascular Systems in the 2nd quarter valued at about $204,000. Advisor Group Inc. lifted its position in Cardiovascular Systems by 0.4% in the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock valued at $263,000 after acquiring an additional 35 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Cardiovascular Systems by 34.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock valued at $265,000 after acquiring an additional 2,115 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in Cardiovascular Systems by 9.5% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 9,193 shares of the medical device company’s stock valued at $296,000 after acquiring an additional 800 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in Cardiovascular Systems in the 3rd quarter valued at about $276,000. Institutional investors own 75.29% of the company’s stock.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.